San Diego, Calif., August 1, 2019 — NanoCellect Biomedical, Inc. (NanoCellect®), in response to litigation filed in United States District Court for the District of Delaware, by Cytonome/ST, LLC (Cytonome), today issued the following:
“We are disappointed that Cytonome chose to resort to the courts, rather than the market, in an unnecessary and unfortunate attempt to restrict access to NanoCellect’s important technology. NanoCellect has developed the leading microfluidics-based cell sorting platform, based on our own patented technology, and intends to challenge Cytonome’s claims against the company,” said Chris Neary, CEO of NanoCellect.
“We have seen a rapid uptake of NanoCellect’s WOLF Cell Sorter platform and laboratories across the country are broadly adopting our technology to advance the understanding of biology. It is extremely gratifying to see the advances researchers are making using our products and services in fields of research like cell line development, genomic sample preparation, CRISPR gene editing, and antibody discovery,” said Dr. José Morachis, President and Co-Founder of NanoCellect.
NanoCellect is a life science tools company manufacturing cell sorters that use proprietary microfluidic technology. NanoCellect’s WOLF® Cell Sorter and N1 single cell plate dispenser allow researchers to analyze and separate biological samples one cell at a time. This enables researchers to isolate cells or populations of interest from the rest of the sample. NanoCellect’s WOLF Cell Sorter uses proprietary, sterile, single-use microfluidic technology. Every part of the fluidics system that touches the sample is disposable, which reduces the risk of cross-contamination between samples. The compact, sturdy, and affordable system can fit almost anywhere, including on a benchtop or in a laminar flow hood.
# # #